Bladder Cancer — Expert Diagnosis, Organ Preservation & Advanced Therapies

The most common and important first symptom of bladder cancer is hematuria — blood in the urine. This can be visible (the urine appears pink, red, or cola-colored) or microscopic (only detectable on urine testing). A critical feature is that it is often painless and can be intermittent — a single episode that resolves is still significant. Other early symptoms include increased urinary frequency, urgency, and discomfort on urination. Any adult with unexplained blood in the urine should be evaluated by a urologist promptly.

This is the most important staging distinction in bladder cancer. Non-muscle-invasive bladder cancer (NMIBC) means the cancer is confined to the inner lining of the bladder and has not grown into the bladder muscle. It is treated with endoscopic resection (TURBT) and intravesical BCG or chemotherapy. Muscle-invasive bladder cancer (MIBC) means the cancer has grown into or through the detrusor muscle layer of the bladder wall. This significantly increases the risk of spread and requires more aggressive treatment — typically radical cystectomy with neoadjuvant chemotherapy, or a bladder-preservation approach.

BCG (Bacillus Calmette-Guérin) is a live attenuated bacterium originally developed as a tuberculosis vaccine. When instilled directly into the bladder (intravesical BCG), it stimulates a powerful local immune response that destroys residual cancer cells and reduces the risk of recurrence and progression in high-risk non-muscle-invasive bladder cancer. It is considered the most effective intravesical treatment for high-risk NMIBC including carcinoma in situ (CIS). BCG is given as an induction course (6 weekly instillations) followed by maintenance instillations over 1–3 years.

Yes, for carefully selected patients. Trimodality therapy (TMT) — combining maximal endoscopic resection (TURBT), external beam radiation therapy to the bladder, and concurrent radiosensitizing chemotherapy — is an established bladder-preservation alternative to radical cystectomy. Studies show that TMT achieves outcomes comparable to cystectomy in patients with solitary tumors, complete initial TURBT, absence of hydronephrosis, and no carcinoma in situ. TMT requires close surveillance cystoscopy after treatment and readiness to proceed with salvage cystectomy if there is residual or recurrent disease.

Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) that targets Nectin-4, a protein expressed on the surface of urothelial cancer cells, and delivers a potent cell-killing agent directly to these cells. In combination with pembrolizumab (an immune checkpoint inhibitor), EV produced superior overall survival compared to platinum-based chemotherapy in the EV-302 trial for previously untreated advanced or metastatic urothelial carcinoma. This combination is rapidly becoming the first-line standard of care for eligible patients with advanced bladder cancer.

For advanced or metastatic urothelial carcinoma, key tests include: FGFR3 mutation and rearrangement testing (for erdafitinib eligibility); PD-L1 CPS (for pembrolizumab first-line in cisplatin-ineligible patients); comprehensive NGS (for HER2, ERCC2, TP53, RB1, TMB, MSI); and, in younger patients, Lynch syndrome assessment. For muscle-invasive disease, ERCC2 mutation status may predict cisplatin chemotherapy sensitivity. These tests should be performed at diagnosis of advanced disease, ideally from a tissue biopsy with concurrent liquid biopsy if tissue is limited.

The majority of bladder cancers are not hereditary and arise from environmental exposures — particularly tobacco smoke and occupational carcinogens. However, a small proportion of bladder cancers are associated with Lynch syndrome, an inherited mismatch repair gene mutation (MLH1, MSH2, MSH6, PMS2) that significantly increases the lifetime risk of multiple cancers including bladder cancer. Young patients, those with a family history of Lynch syndrome-associated cancers, or those with MSI-H bladder cancer should be referred for germline genetic testing.

Follow-up intensity depends on stage and treatment. For NMIBC, regular surveillance cystoscopy is required — typically every 3 months for the first 2 years, then at 6-monthly and annual intervals depending on risk group. Urine cytology and upper tract imaging are part of the surveillance schedule. After radical cystectomy, surveillance includes CT imaging, renal function monitoring, and vitamin B12 assessment (for ileal conduit patients). After systemic therapy for advanced disease, CT or PET-CT every 2–3 months during active treatment, then at regular intervals, monitors response and recurrence.

Yes. CancerFax provides specialist support for bladder cancer patients at all stages of their treatment journey. We review cystoscopy reports, TURBT pathology, staging CT/MRI, molecular profiling results, and treatment history, then connect patients with expert uro-oncologists and bladder cancer surgeons — in India, Germany, South Korea, the UAE, and other countries with specialist bladder cancer programs. We assist with second opinions on cystectomy versus bladder preservation, guidance on FGFR3-targeted therapy and ADC access, clinical trial identification, and end-to-end coordination for international treatment options.